Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1
- PMID: 11876761
- PMCID: PMC1906331
- DOI: 10.1046/j.1365-2249.2002.01733.x
Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1
Abstract
Strongyloidiasis, a human intestinal infection caused by Strongyloides stercoralis (S. stercoralis), is difficult to cure with drugs. In particular, a decrease of the efficacy of treatment has been reported in patients dually infected with S. stercoralis and human T-cell leukaemia virus type I (HTLV-I), both of which are endemic in Okinawa, Japan. However, the factors influencing this resistance remain unclear. In the present study, patients infected with S. stercoralis, with or without HTLV-I infection, were treated with albendazole, followed up for one year and separated into two groups, cured and non-cured. The cure rate of S. stercoralis was lower in HTLV-I carriers (P < 0.05). Serum levels of S. stercoralis-specific IgA, IgE, IgG, IgG1 and IgG4 antibodies were estimated, and a decrease of IgE (P < 0.05) and an increase of IgG4 (P < 0.05) were observed in the non-cured group, especially in HTLV-I carriers. RT-PCR of cytokines using peripheral blood mononuclear cells revealed that S. stercoralis patients with HTLV-I showed a high frequency of expression of IFN-gamma and TGF-beta1, whereas those without HTLV-I showed no expression of these cytokines. IFN-gamma- and TGF-beta1-positive HTLV-I carriers showed a decrease of IgE (P < 0.05), an increase of IgG4 (P < 0.01) and a lower cure rate (P < 0.01) compared with those who were negative for both cytokines. These results suggest that persistent infection with HTLV-I affected S. stercoralis-specific immunity and reduced therapeutic efficacy.
Figures

Similar articles
-
Production of a high level of specific IgG4 antibody associated with resistance to albendazole treatment in HLA-DRB1*0901-positive patients with strongyloidiasis.Am J Trop Med Hyg. 1999 Oct;61(4):668-71. doi: 10.4269/ajtmh.1999.61.668. Am J Trop Med Hyg. 1999. PMID: 10548308
-
Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis.J Infect Dis. 1998 Dec;178(6):1856-9. doi: 10.1086/314507. J Infect Dis. 1998. PMID: 9815251
-
Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan.Am J Trop Med Hyg. 1997 Jan;56(1):71-5. doi: 10.4269/ajtmh.1997.56.71. Am J Trop Med Hyg. 1997. PMID: 9063365
-
Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis.Parasite Immunol. 2004 Nov-Dec;26(11-12):487-97. doi: 10.1111/j.0141-9838.2004.00726.x. Parasite Immunol. 2004. PMID: 15771684 Review.
-
[Clinical and immunological consequences of the association between HTLV-1 and strongyloidiasis].Rev Soc Bras Med Trop. 2002 Nov-Dec;35(6):641-9. doi: 10.1590/s0037-86822002000600016. Epub 2003 Feb 26. Rev Soc Bras Med Trop. 2002. PMID: 12612748 Review. Portuguese.
Cited by
-
Strongyloides stercoralis infection in the immunocompromised host.Curr Infect Dis Rep. 2008 May;10(2):105-10. doi: 10.1007/s11908-008-0019-6. Curr Infect Dis Rep. 2008. PMID: 18462583 Free PMC article.
-
Human T-Cell Lymphotropic Virus Type 1 and Strongyloides stercoralis Co-infection: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2022 Feb 14;9:832430. doi: 10.3389/fmed.2022.832430. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35237633 Free PMC article.
-
HTLV-1 modifies the clinical and immunological response to schistosomiasis.Clin Exp Immunol. 2004 Aug;137(2):424-9. doi: 10.1111/j.1365-2249.2004.02508.x. Clin Exp Immunol. 2004. PMID: 15270862 Free PMC article.
-
Strongyloides stercoralis: Global Distribution and Risk Factors.PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2288. doi: 10.1371/journal.pntd.0002288. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23875033 Free PMC article. Review.
-
Strongyloidiasis: what every gastroenterologist needs to know.Ther Adv Chronic Dis. 2022 Nov 15;13:20406223221137499. doi: 10.1177/20406223221137499. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 36407019 Free PMC article. Review.
References
-
- Clark JW, Guroff MR, Ikehara O, et al. Human T-cell leukemia-lymphoma virus type 1 and adult T-cell leukemia-lymphoma in Okinawa. Cancer Res. 1985;45:2849–52. - PubMed
-
- Sato Y, Toma H, Takara M, et al. Application of enzyme-linked immunosorbent assay for mass examination of strongyloidiasis in Okinawa. Japan Int J Parasitol. 1990;20:1025–9. - PubMed
-
- Gessain A, Barin F, Vernant JC, et al. Antibodies to human T lymphotropic virus type-I in patients with tropic spastic paraparesis. Lancet. 1985;2:407–10. - PubMed
-
- Osame M, Usuku K, Izumo S, et al. HTLV-I-associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–2. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous